Trial Profile

An 8-Week Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Oral Fispemifene for the Treatment of Sexual Dysfunction in Hypogonadal Men

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fispemifene (Primary)
Indications Hypogonadism; Lower urinary tract symptoms; Prostatitis
Focus Proof of concept; Therapeutic Use
Sponsors NexMed (USA)

Most Recent Events

28 Mar 2016 Primary endpoint has not been met, (Change in IIEF-EF (International Index of Erectile Function - erectile function domain) score), according to Apricus Biosciences media release.
28 Mar 2016 Top-line results of this trial published in an Apricus Biosciences media release.
06 Jan 2016 According to Apricus media release, company is planning to report top-line data of this trial in the first quarter of 2016.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com